|Bid||58.25 x 1300|
|Ask||58.32 x 2200|
|Day's Range||58.01 - 58.72|
|52 Week Range||46.48 - 60.93|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||38.42|
|Forward Dividend & Yield||1.40 (2.42%)|
|Ex-Dividend Date||Feb. 25, 2021|
|1y Target Est||65.47|
Dr. Shikha Jain, Assistant Professor of Medicine, University of Illinois Chicago, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
WILMINGTON, Del., July 23, 2021--AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise.
A look at the shareholders of AstraZeneca PLC ( LON:AZN ) can tell us which group is most powerful. Institutions will...